Finance

Laboratory reports fiscal 2005 earnings

Published in Medical Letter on the CDC and FDA, June 19th, 2005

Mylan Laboratories Inc. (MYL) announced that it will host a strategic business update and investor presentation to review the company's fiscal 2005 financial results and recent operational highlights and discuss the outlook and strategies for fiscal 2006, including an update on nebivolol, Mylan's proprietary hypertension product.

The timing of the strategic business update is the result of nebivolol's Prescription Drug User Fee Act (PDUFA) date, which is currently scheduled for May 31, 2005. Mylan is also scheduling a non-deal investor roadshow following the strategic business update.

"We are pleased that we were able to achieve the high end of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry